Publications by authors named "Neil M H Graham"

Claim this Profile
D
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
G Walter Canonica, Arnaud Bourdin, Anju T Peters, Martin Desrosiers, Claus Bachert, Neil M H Graham

J Allergy Clin Immunol Pract· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Joaquim Mullol, Claus Bachert, Nikhil Amin, Martin Desrosiers, Peter W Hellings, Neil M H Graham

J Allergy Clin Immunol Pract· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.
Jonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, Michael J Cork, Marjolein de Bruin-Weller, Neil M H Graham

Dermatitis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
William W Busse, Sally E Wenzel, Thomas B Casale, J Mark FitzGerald, Megan S Rice, Neil M H Graham

Lancet Respir Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST.
Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Neil M H Graham

Allergy· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Jennifer D Hamilton, Sivan Harel, Brian N Swanson, William Brian, Zhen Chen, Neil M H Graham

Clin Exp Allergy· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Tanya M Laidlaw, Claus Bachert, Nikhil Amin, Martin Desrosiers, Peter W Hellings, Neil M H Graham

Ann Allergy Asthma Immunol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
Mark Boguniewicz, Lisa A Beck, Lawrence Sher, Emma Guttman-Yassky, Diamant Thaçi, Neil M H Graham

J Allergy Clin Immunol Pract· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Ashish Bansal, Eric L Simpson, Amy S Paller, Elaine C Siegfried, Andrew Blauvelt, Neil M H Graham

Am J Clin Dermatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
Ian D Pavord, Salman Siddiqui, Alberto Papi, Jonathan Corren, Lawrence D Sher, Neil M H Graham

J Asthma Allergy· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
William W Busse, Jorge F Maspero, Yufang Lu, Jonathan Corren, Nicola A Hanania, Neil M H Graham

Ann Allergy Asthma Immunol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Amy S Paller, Elaine C Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J Cork, Neil M H Graham

J Am Acad Dermatol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Kazuhiko Arima, Neil M H Graham

Allergol Int· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Anita Boyapati, Sergio Schwartzman, Jérôme Msihid, Ernest Choy, Mark C Genovese, Neil M H Graham

Arthritis Rheumatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data.
Pavel Kovalenko, John D Davis, Meng Li, Ronda Rippley, Marius Ardeleanu, Neil M H Graham

Clin Pharmacol Drug Dev· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Lisa A Beck, Diamant Thaçi, Mette Deleuran, Andrew Blauvelt, Robert Bissonnette, Neil M H Graham

Am J Clin Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Jonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, Brian S Kim, Jashin J Wu, Neil M H Graham

J Am Acad Dermatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Cem Gabay, Gerd R Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Neil M H Graham

Arthritis Res Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Claus Bachert, S James Zinreich, Peter W Hellings, Joaquim Mullol, Daniel L Hamilos, Neil M H Graham

Rhinology· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Amy S Paller, Ashish Bansal, Eric L Simpson, Mark Boguniewicz, Andrew Blauvelt, Neil M H Graham

Am J Clin Dermatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Margitta Worm, Eric L Simpson, Diamant Thaçi, Robert Bissonnette, Jean-Philippe Lacour, Neil M H Graham

JAMA Dermatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Ikuo Hirano, Evan S Dellon, Jennifer D Hamilton, Margaret H Collins, Kathryn Peterson, Neil M H Graham

Gastroenterology· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Eric L Simpson, Amy S Paller, Elaine C Siegfried, Mark Boguniewicz, Lawrence Sher, Neil M H Graham

JAMA Dermatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
Mario Castro, Klaus F Rabe, Jonathan Corren, Ian D Pavord, Constance H Katelaris, Neil M H Graham

ERJ Open Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Claus Bachert, Joseph K Han, Martin Desrosiers, Peter W Hellings, Nikhil Amin, Neil M H Graham

Lancet· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis